Cyclic Peptides for TLR4 Co-Receptor Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunomodulatory approaches lack effective peptides that can specifically bind to Toll-like receptor 4 (TLR4) co-receptors, such as MD2 and CD14, to modulate inflammatory signaling independently of other activators, and there is a need for peptides that can activate or inhibit TLR4 signaling in a dose-dependent manner.
Innovation Solution
Development of cyclic backbone peptides with specific sequences that bind to MD2 and CD14, which are computationally designed to activate or inhibit TLR4 signaling, demonstrated to interact with TLR4 co-receptors and modulate downstream signaling independently of other activators, as shown by predicted binding energy contributions and experimental validation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional immunomodulatory approaches are used, then general immune modulation is achieved, but specific binding to TLR4 co-receptors (MD2 and CD14) is not possible
Solution Approach 1:
The invention divides the TLR4 signaling modulation into independent components by designing peptides that specifically target individual co-receptors (MD2 or CD14) rather than acting on TLR4 generally. This segmentation allows independent modulation of signaling pathways through specific co-receptor engagement, resolving the contradiction between specificity and adaptability.
Solution Approach 2:
The peptides are designed with specific local structures and sequences that confer affinity for particular co-receptors (MD2 or CD14). By localizing the binding specificity to particular co-receptor regions, the invention enables precise modulation of TLR4 signaling at the co-receptor level while maintaining the ability to activate or inhibit signaling independently.
2Reliability
If peptides are designed to bind TLR4 co-receptors specifically, then independent modulation of signaling is achieved, but the complexity of peptide sequence design increases
Solution Approach 1:
The invention systematically varies key parameters of the peptide sequences (amino acid composition, cyclic backbone structure, length) to optimize binding affinity and specificity for TLR4 co-receptors. By changing these parameters in a controlled manner, the invention achieves reliable independent signaling modulation while managing design complexity through structured parameter optimization.
3Strength
If cyclic backbone peptides are used instead of linear peptides, then binding affinity to TLR4 co-receptors is improved, but the difficulty of synthesis and purification increases
Solution Approach 1:
The cyclic peptide synthesis is segmented into manageable steps using standard organic chemistry methodologies. The cyclic backbone is formed through controlled cyclization reactions that can be performed in multiple steps, allowing for improved binding affinity while maintaining feasibility of synthesis and purification through established chemical techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides achieve independent activation or inhibition of TLR4 signaling, demonstrating potential as immunomodulatory agents for vaccine adjuvants and pharmaceutical compositions, capable of blocking or enhancing immune responses in a controlled manner.
Implementation Method 1
cyclic backbone peptides that bind TLR4 with at least one of co-receptors myeloid differentiation factor 2 (MD2) and cluster of differentiation 14 (CD14)
Data Source
Figure 1A
Figure 1A
Figure 1A
AI summary
A group of peptides is provided which activate or inhibit toll-like receptor 4 (TLR4) and may be used to modulate inflammatory signaling and host defense pathways. The peptides were derived in silico and tested in vitro in cell cultures. These peptides may be used in the preparation of immunomodulatory compositions such as vaccine adjuvants and in pharmaceutical compositions for immunomodulation of the innate immune system such as vaccine adjuvants. The peptides may also be used in the preparation of TLR4 activators, TLR4 inhibitors and MD2 labels, e.g., for research purposes.